Cytovance Biologics, Inc., a contract manufacturer of mammalian and microbial biologics, has formed a development and manufacturing agreement with Selexys Pharmaceuticals, Corp., an Oklahoma City-based clinical-stage biopharmaceutical company.  

Selexys Pharmaceuticals is developing drugs that target certain underlying mechanisms of inflammatory diseases and cancer. SELK2 is an investigational humanized monoclonal antibody directed toward the treatment of Crohn's disease and multiple myeloma. Selexys has contracted Cytovance Biologics as its CMO to provide process development, scale-up, and cGMP manufacturing services of SELK2 in support of a Phase I human clinical trial.

Cytovance Biologics operates from facilities at the OU University Research Park in Oklahoma City, Oklahoma. This site includes more than 50,000 square feet of cGMP manufacturing cleanroom space, an adjacent facility that houses the quality control laboratories, and additional facilities that house the company’s process development, analytical development, and administrative functions.

Cytovance is constructing a new 30,000-square foot greenfield facility to house the GMP warehousing operations and future manufacturing expansions. The new facility is located three miles north of the company’s existing facilities. This building will come on line in mid-2014.

Source: Cytovance Biologics